Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Short Bowel Syndrome Market In 2029?

Recent years have witnessed a swift expansion in the market size for short bowel syndrome. The industry is predicted to continue this growth trajectory, escalating from a worth of $2.69 billion in 2024 to approximately $3.08 billion in 2025 – a compound annual growth rate (CAGR) of 14.6%. This advancement during the historic era can be ascribed to factors like a rising incidence of gastrointestinal issues, escalated healthcare expenditure and insurance coverage, enhanced post-operative care for short bowel syndrome patients, an upsurge in the occurrence of Crohn’s disease and other related gastrointestinal disorders, and the upgrades in parenteral nutrition formulas and their administration methods.

In the coming years, the market size of short bowel syndrome stands to witness accelerated expansion, projected to reach$5.29 billion by the year 2029, growing at a compound annual growth rate (CAGR) of 14.4%. The projected escalation within this timeframe can be linked to the escalation in short bowel syndrome (SBS) cases, the increased usage of parenteral and enteral nutritional therapies, surge in clinical research and pharmaceutical innovation, heightened healthcare spending, and improved early discovery and awareness about SBS. During this period, we anticipate innovations in intestinal rehabilitation therapies, further progress in small intestine transplant methods, the application of telemedicine for managing SBS, advancements in technology for enteral feeding apparatus, and the integration of artificial intelligence in planning SBS treatment to be the prominent trends.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

Which Primay Drivers Are Accelerating Growth in the Short Bowel Syndrome Market?

The escalating occurrence of gastrointestinal conditions is anticipated to fuel the expansion of the short bowel syndrome market in the future. Gastrointestinal ailments encompass a wide array of disorders impacting the digestive system, which consist of conditions affecting the stomach, intestines, liver, and pancreas often resulting in compromised digestion and nutrient intake. The augmentation in the occurrence of gastrointestinal ailments is primarily influenced by unhealthy eating habits, which disturb gut health and encourage inflammation. These diseases can lead to the development of short bowel syndrome as they may require surgical removal of impaired intestinal segments, causing a reduction in absorption capability. For example, in September 2023, the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canadian organization dedicated to enhancing the lives of patients afflicted with Crohn’s disease and ulcerative colitis, stated that there was a prevalence of 825 per 100,000 in 2023, meaning over 320,000 individuals in Canada suffer from inflammatory bowel disease (IBD). Since the prevalence is projected to rise by 2.44% annually, about 1.1% of the population or approximately 470,000 Canadians are expected to be living with IBD by 2035. Therefore, the escalating occurrence of gastrointestinal conditions is steering the growth of the short bowel syndrome market.

Which Primary Segments of the Short Bowel Syndrome Market Are Driving Growth and Industry Transformations?

The short bowel syndromemarket covered in this report is segmented –

1) By Type: Glucagon-Like Peptide (GLP-2); Growth Hormone; Glutamine

2) By Diagnosis: Physical Exam; Blood Tests; Fecal Fat Tests; Imaging Procedures; Other Diagnosis

3) By Treatment: Nutritional Therapy; Medications; Surgery; Transplant

4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Other Distribution Channels

Subsegments:

1) By Glucagon-Like Peptide (GLP-2): Teduglutide; Other GLP-2 Analogues

2) By Growth Hormone: Somatropin; Other Growth Hormone Therapies

3) By Glutamine: Oral Glutamine; Intravenous Glutamine

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Short Bowel Syndrome Market?# Market?

North America was the largest region in the short bowel syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Short Bowel Syndrome Industry Dynamics?

Leading businesses in the short bowel syndrome market are honing their focus on pioneering progress in medical science. This includes establishing innovative treatment methods for intestinal failure, which could offer a cutting-edge therapeutic solution designed to optimize treatment results for patients suffering from gastrointestinal disorders. In this context, intestinal failure is a severe disorder where the individual’s small intestine fails to sufficiently absorb nutrients, fluids, and electrolytes to sustain adequate hydration and nutrition. For example, in May 2024, Ironwood Pharmaceuticals, Inc., a renowned healthcare company based in the US, disclosed new research data linked to the evaluation of apraglutide in adults diagnosed with short bowel syndrome and intestinal failure (SBS-IF). Apraglutide, a cutting-edge GLP-2 analog, showed potential in improving intestinal absorption and lessening dependence on parenteral support. This research underlines the efficacy, safety, and lasting benefits of the drug, showcasing Ironwood’s commitment to the development of innovative treatments for gastrointestinal disorders.

View the full report here:

https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

What Parameters Are Used to Define the Short Bowel Syndrome Market?

Short bowel syndrome (SBS) is a malabsorption disorder caused by the loss or dysfunction of a significant portion of the small intestine, leading to impaired nutrient and fluid absorption. It often results in diarrhea, dehydration, electrolyte imbalances, and malnutrition. The severity of symptoms depends on the remaining intestinal length and its ability to adapt. SBS can significantly impact overall health, requiring careful dietary and medical management.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23515

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model